Short Interest in UCB SA (OTCMKTS:UCBJY) Expands By 200.0%

UCB SA (OTCMKTS:UCBJY) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 300 shares, a growth of 200.0% from the August 31st total of 100 shares. Based on an average daily volume of 7,700 shares, the short-interest ratio is currently 0.0 days.

UCB Price Performance

UCBJY opened at $91.67 on Friday. The company’s 50 day simple moving average is $86.89 and its 200-day simple moving average is $74.43. UCB has a one year low of $34.85 and a one year high of $94.16.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.